Article
Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
Pediatric pulmonology - 1 Jun 2007
Nguyen Dao, Emond Mary J, Mayer-Hamblett Nicole, Saiman Lisa, Marshall Bruce C, Burns Jane L
Abstract excerpt
A 6-month clinical trial of azithromycin (AZM) in American cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection showed clinical improvement without significant reduction in bacterial density. Sub-inhibitory AZM has been hypothesized to affect P. aeruginosa virulence, partly contributing to the mechanism of action of AZM. To correlate bacterial phenotypes of P. aeruginosa isolates with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
